Katherine A Hirchak1, Abram J Lyons2, Jalene L Herron3, Gordon Kordas1, Jennifer L Shaw4, Kelley Jansen5, Jaedon P Avey4, Sterling M McPherson6, Dennis Donovan7, John Roll8, Dedra Buchwald9, Richard Ries10, Michael G McDonell11. 1. Department of Community and Behavioral Health, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA. 2. Department of Community and Behavioral Health, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA; School of Social Policy & Practice, University of Pennsylvania, Philadelphia, PA, USA. 3. Center on Alcoholism, Substance Abuse and Addictions, University of New Mexico, Albuquerque, NM, USA; Department of Psychology, University of New Mexico, Albuquerque, NM, USA. 4. Southcentral Foundation, Anchorage, AK, USA. 5. Southcentral Foundation, Anchorage, AK, USA; Department of Psychology, University of Montana, Missoula, MT, USA. 6. Department of Community and Behavioral Health, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA; Institute for Research and Education to Advance Community Health, Washington State University, Spokane, WA, USA. 7. Alcohol and Drug Abuse Institute, University of Washington, Seattle, WA, USA; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA. 8. Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA. 9. Department of Community and Behavioral Health, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Institute for Research and Education to Advance Community Health, Washington State University, Spokane, WA, USA. 10. Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA. 11. Department of Community and Behavioral Health, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA; Institute for Research and Education to Advance Community Health, Washington State University, Spokane, WA, USA. Electronic address: mmcdonell@wsu.edu.
Abstract
OBJECTIVE: Determine whether a culturally tailored contingency management (CM) intervention targeting alcohol abstinence resulted in secondary effects on cannabis use among American Indian and Alaska Native (AI/AN) adults. METHODS: The research team conducted this secondary data analysis to examine cannabis abstinence using data from a randomized control trial of CM for alcohol use among three AI/AN-serving organizations. One hundred and fifty-eight adults met the randomization criteria (i.e., submission of 50% or more urine samples and one alcohol-positive urine test during a 4-week, pre-randomization, observation period). For 12 weeks after randomization, participants received incentives for submitting a urine test negative for ethyl glucuronide (EtG < 150 ng/mL, CM group) or incentives for submitting a urine sample regardless of abstinence (Non-contingent [NC] Control group). Generalized linear mixed effects models assessed group differences in cannabis abstinence during the intervention, verified by urine tetrahydrocannabinol negative tests (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid <50 ng/mL). RESULTS: At baseline, 42.2% (n = 35) of participants in the NC group and 40.0% (n = 30) of those in the CM group had a cannabis positive urine test. An overall intervention by time interaction was detected for a cannabis negative urine test (χ2 = 13.40, p = 0.001). Compared to the NC group, the CM group had 3.92 (95% CI:1.23-12.46) times higher odds of having a cannabis negative urine test during the intervention period and 5.13 (95% CI:1.57-16.76) times higher odds of having a negative cannabis test at the end of intervention period. CONCLUSION: CM addressing alcohol misuse may be an effective strategy for decreasing cannabis use among AI/AN adults. TRIAL REGISTRATION: ClinicalTrials.gov number, Identifier: NCT02174315.
OBJECTIVE: Determine whether a culturally tailored contingency management (CM) intervention targeting alcohol abstinence resulted in secondary effects on cannabis use among American Indian and Alaska Native (AI/AN) adults. METHODS: The research team conducted this secondary data analysis to examine cannabis abstinence using data from a randomized control trial of CM for alcohol use among three AI/AN-serving organizations. One hundred and fifty-eight adults met the randomization criteria (i.e., submission of 50% or more urine samples and one alcohol-positive urine test during a 4-week, pre-randomization, observation period). For 12 weeks after randomization, participants received incentives for submitting a urine test negative for ethyl glucuronide (EtG < 150 ng/mL, CM group) or incentives for submitting a urine sample regardless of abstinence (Non-contingent [NC] Control group). Generalized linear mixed effects models assessed group differences in cannabis abstinence during the intervention, verified by urine tetrahydrocannabinol negative tests (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid <50 ng/mL). RESULTS: At baseline, 42.2% (n = 35) of participants in the NC group and 40.0% (n = 30) of those in the CM group had a cannabis positive urine test. An overall intervention by time interaction was detected for a cannabis negative urine test (χ2 = 13.40, p = 0.001). Compared to the NC group, the CM group had 3.92 (95% CI:1.23-12.46) times higher odds of having a cannabis negative urine test during the intervention period and 5.13 (95% CI:1.57-16.76) times higher odds of having a negative cannabis test at the end of intervention period. CONCLUSION: CM addressing alcohol misuse may be an effective strategy for decreasing cannabis use among AI/AN adults. TRIAL REGISTRATION: ClinicalTrials.gov number, Identifier: NCT02174315.
Authors: Michael Gerard McDonell; Emily Leickly; Sterling McPherson; Jordan Skalisky; Katherine Hirchak; Oladunni Oluwoye; Debra Srebnik; John Michael Roll; Richard Kirkland Ries Journal: Am J Addict Date: 2017-08-18
Authors: Sterling McPherson; Michael Orr; Crystal Lederhos; Michael McDonell; Emily Leickly; Katherine Hirchak; Oladunni A Oluwoye; Sean M Murphy; Matthew Layton; John M Roll Journal: Behav Pharmacol Date: 2018-06 Impact factor: 2.293
Authors: Sean M Murphy; Michael G McDonell; Sterling McPherson; Debra Srebnik; Frank Angelo; John M Roll; Richard K Ries Journal: Drug Alcohol Depend Date: 2015-05-14 Impact factor: 4.492
Authors: Michael G McDonell; Emily Leickly; Sterling McPherson; Jordan Skalisky; Debra Srebnik; Frank Angelo; Roger Vilardaga; Jenny R Nepom; John M Roll; Richard K Ries Journal: Am J Psychiatry Date: 2017-01-31 Impact factor: 18.112
Authors: Sean M Murphy; Aimee N C Campbell; Udi E Ghitza; Tiffany L Kyle; Genie L Bailey; Edward V Nunes; Daniel Polsky Journal: Drug Alcohol Depend Date: 2016-01-30 Impact factor: 4.492
Authors: Michael G McDonell; Debra Srebnik; Frank Angelo; Sterling McPherson; Jessica M Lowe; Andrea Sugar; Robert A Short; John M Roll; Richard K Ries Journal: Am J Psychiatry Date: 2013-01 Impact factor: 18.112
Authors: Michael G McDonell; Katherine A Hirchak; Jalene Herron; Abram J Lyons; Karl C Alcover; Jennifer Shaw; Gordon Kordas; Lisa G Dirks; Kelley Jansen; Jaedon Avey; Kate Lillie; Dennis Donovan; Sterling M McPherson; Denise Dillard; Richard Ries; John Roll; Dedra Buchwald Journal: JAMA Psychiatry Date: 2021-06-01 Impact factor: 21.596
Authors: Michael G McDonell; Jordan Skalisky; Ekaterina Burduli; Albert Foote; Alexandria Granbois; Kenneth Smoker; Katherine Hirchak; Jalene Herron; Richard K Ries; Abigail Echo-Hawk; Celestina Barbosa-Leiker; Dedra Buchwald; John Roll; Sterling M McPherson Journal: Addiction Date: 2021-01-14 Impact factor: 7.256